In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Unicycive Therapeutics (UNCY – Research Report), with a price target of $7.50.
Ed Arce has given his Buy rating due to a combination of factors that highlight Unicycive Therapeutics’ promising prospects for 2025. The company is on the brink of significant milestones, including the anticipated PDUFA date for their lead asset, oxylanthanum carbonate (OLC), which is expected to be approved for treating hyperphosphatemia in chronic kidney disease patients on dialysis. This potential approval, along with the planned commercial launch of OLC later in the year, positions Unicycive for substantial stock appreciation.
OLC’s differentiated profile, including its high potency, reduced pill burden, and improved palatability, sets it apart from existing FDA-approved phosphate binders. The pivotal study results, showing a high success rate in achieving serum phosphate control, further bolster its potential market impact. Additionally, Unicycive’s strategic focus on building a targeted salesforce and establishing a commercial infrastructure indicates a well-prepared approach for the upcoming product launch, reinforcing the Buy recommendation.
According to TipRanks, Arce is a 5-star analyst with an average return of 13.3% and a 45.09% success rate. Arce covers the Healthcare sector, focusing on stocks such as Arcturus Therapeutics, Akebia Therapeutics, and Pliant Therapeutics.